Revenue Update on Alder Biopharmaceuticals Inc(NASDAQ:ALDR)

Alder Biopharmaceuticals Inc(NASDAQ:ALDR) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 26, 2016. Company reported revenue of $113.00K. Analysts estimated a revenue of $1.14M. Earnings per share were $-0.79. Analysts had estimated an EPS of $-0.75.

Alder Biopharmaceuticals Inc (ALDR) made into the market gainers list on Fridays trading session with the shares advancing 5.14% or 1.57 points. Due to strong positive momentum, the stock ended at $32.1, which is also near the day’s high of $32.38. The stock began the session at $30.5 and the volume stood at 8,37,237 shares. The 52-week high of the shares is $48.5 and the 52 week low is $15.8201. The company has a current market capitalization of $1,611 M and it has 5,01,84,886 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 15, 2016, Mark James Litton (Chief Business Officer) sold 6,000 shares at $29.25 per share price.Also, On Jun 7, 2016, Jeffrey T L Smith (Sr. VP Translational Medicine) sold 16,090 shares at $30.87 per share price.On Jun 3, 2016, Randall C Schatzman (President and CEO) sold 10,000 shares at $29.88 per share price, according to the Form-4 filing with the securities and exchange commission.

Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. The Company’s pipeline includes ALD403 Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6) and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH) and is being developed for the treatment of Cushing’s disease.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *